Clear cell endometrial cancer: a CTF multicentre Italian study

Endometrial clear cell carcinoma (CCC) is a rare entity and only accounts for 1-6% of all endometrial cancers. CCC is considered an aggressive subtype of endometrial cancer with worse prognosis compared with type I cancer and more frequent relapses at distant and extrapelvic sites. These characteristics require specific treatment modalities, but rarity of the disease does not allow to identify evidence based indications for therapies. Objective of the present study is to analyse a series of cases treated in a multicentre Italian setting. Materials and Methods: Sixty-five endometrial CCC were treated in the period 1990-2010 in the participating institutions. Slides of the pathological specimens were reviewed by a single pathologist of each institution and debatable cases were collegially reviewed. Clinical records were collected by a common database. Demographic, surgical pathological, and follow-up data were registered. Results: All patients received primary surgery. Stage of disease according FIGO 2009 was as follow: 1a: 16.9%, 1b: 35.4%, 2: 9.2%, 3a: 9.2%, 3b: 3.1%, 3c: 16.9%, 4a: 3.1%, and 4b: 6.1%. Adjuvant post-operative treatment was adopted in 53.8% of cases. A relapse was detected in 29.2% of cases with a majority of extrapelvic sites (68.4%). Five-year survival rate was significantly related to stage of disease with an excellent prognosis for Stage Ia e Ib disease with a complete staging. In these cases adjuvant treatment does not show significant improvement of survival. Relapsed cases show a response rate to treatment in 26% of cases (predominantly chemotherapy). Conclusion: CCC requires extensive surgical staging. Stage I disease completely staged does not require adjuvant therapy. More advanced stages require adjuvant chemotherapy.

Clear cell endometrial cancer; Post-treatment relapses; Clinical outcome.

[1] American Cancer Society: “Cancer Facts and Figures 2012”. Atlanta, GA, 2012. Available at: https://www.google.it/url?sa= t&rct=j&q= &esrc=s&source=web&cd=1&ved=0CCEQFjAA&url=http%3A%2F%2Fpressroom.cancer.org%2Fdownload%2F2012%2BCancer%2BFa cts%2B%2526%2BFigures.pdf&ei=gWkyVZKjH8-V7AbM4YHwDQ&usg=AFQjCNHo1_zhIlAdehbjPfrR12EZAPh22 A&bvm=bv.91071109,d.ZWU

[2] AIOM/AIRTOM: “I numeri del Cancro in Italia 2011”. Brescia: In-termedia Editor, 2011, 16.

[3] Ueda S.M., Kapp D.S., Cheung M.K., Shin J.Y., Osann K., Husain A., et al.: “Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the in-creasing number of deaths”. Am. J. Obstet Gynec., 2008, 198, 218.e1.

[4] Cirisano F.D. Jr., Robboy S.J., Dodge R.K., Bentley R.C., Krigman H.R., Synan I.S., et al.: “Epidemiopathologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma”. Gynecol. Oncol., 1999, 74, 385.

[5] Olawaiye A.B., Boruta D.M. 2nd.: “Management of women with clear cell endometrial cancer: a Society of Gynecologic Oncology (SGO) review”. Gynecol. Oncol., 2009, 113, 277.

[6] Hinshaw H.D., Smith A., Rungruang B., Kelley J.L. Jr., Beriwal S., Krivak T.C., et al.: “The risk of subsequent malignancies in women with uterine papillary serous or clear cell endometrial can-cers”. Int. J. Gynecol. Cancer, 2013, 23, 1044.

[7] Acharia S., Hensley M.I., Montag A.C., Fleming G.F.: “Rare uterine cancers”. Lancet Oncol., 2005, 6, 961.

[8] Felix A.S., Stone R.A., Browser R., Chivukula M., Edwards R.P., Weissfeld J.L., Linkov F.: “Comparison of survival outcomes be-tween patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers”. Int, J. Gynecol. Cancer, 2011, 21, 877.

[9] Creasman W.T., Kholer M.F., Odicino F., Maisonneuve P., Boyle P.: “Prognosis of papillary serous, clear cell and grade 3 stage I carci-noma of the endometrium”. Gynecol. Oncol., 2004, 95, 593.

[10] Pecorelli S.: “Revised FIGO stagingfor carcinoma of the vulva, cervix and endometrium”. Int. J. Gynaecol. Obstet., 2009, 105, 103.

[11] McMeekin D.S., Filiaci V.L., Thigpen J.T., Gallion H.H., Fleming G.F., Rodgers W.H., Gynecologic Oncology Group study: “The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a GOG study”. Gynecol. Oncol., 2007, 106, 16.

[12] Modesitt S.C., Tian C., Kryscio R., Thigpen J.T., Randall M.E., Gallion H.H., et al.: “Impact of body mass index on treatment outcomes in Endometrial cancer patients receiving Doxorubucin and Cisplatin: a GOG study”. Gynecol. Oncol., 2007, 105, 59.

[13] Clement P.B., Young R.H.: “Non endometriod carcinomas of the uterine corpus: a review of their pathology with recent advances in problematic aspects”. Adv. Anat. Pathol., 2004, 11, 117.

[14] Huang G.S., Gebb J.S., Einstein M.H., Shahabi S., Novetsky A.P., Goldberg G.L.: “Accuracy of preoperative endometrial sampling for the detection of high grade endometrial tumors”. Am. J. Obstet. Gynecol., 2007, 196, 243.e1.

[15] Thomas M., Mariani A., Wright J.D., Madarek E.O., Powell M.A.,Mutch D.G., et al.: “Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multistitutional review”. Gynecol. Oncol., 2008, 108, 293.

[16] Alektiar K.M., McKee A., Lin O., Venkatraman E., Zelefsky M.J., McKee B., et al.: “Is there a difference in outcome between stage III endometrial cancer of papillary serous clear cell and endometriodi grade 3 cancer?” Int. J. Radiat. Oncol. Biol Phys., 2002, 54, 79.

[17] Gadducci A., Cosio S., Landoni F., Maggino T., Zola P., Fuso L., Sartori E.: “ Analysis of treatment failures and survival of patientswith uterine papillary serous carcinoma: a cooperative task force (CTF) Study”. Int. J. Gynecol. Cancer, 2012, 22, 1355.

[18] Mundt A.J., Murphy K.T., Rotmensch J., Waggoner S.E., Yamada S.D., Connell P.P.: “Surgery and postoperative radiation therapy in FIGO stage IIIc endometrial carcinoma”. Int. J. Radiat. Oncol. Biol. Phys., 2001, 50, 1154.

[19] Sutton G., Axelrod J.H., Bundy B.N., Roy T., Homesley H., Lee R.B., et al.: “Adjuvant whole abdominal irradiation in stage I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group”. Gynecol. Oncol., 2006, 100, 349.

[20] Murphy K.T., Rotmensch J., Yamada S.D., Mundt A.J.: “Outcome and patterns of failure in pathologic stage I-IV clear cell carcinoma of the endometrium: implications for adjuvant radiation therapy”. Int. J. Rad. Oncol. Biol Phys., 2003, 55, 1272.

[21] Sovak M.A, Dupont J., Hensley M.L., Ishill N., Gerst S., Abu-Rustum N., et al.: “Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study. Int. J. Gynecol. Cancer, 2007, 17, 197.

[22] Pignata S, Scambia G, Pisano C., Breda E, Di Maio M, Greggi S., et al. A Multicenter phase II study of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy for patients with advanced or recurrent endometrial carcinoma. Br. J. Cancer, 2007, 96, 1639.

[23] Michener C.M., Peterson G., Kulp B., Webster K.D., Markman M.: “Carboplatin plus placlitaxel in the treatment of advanced or recurrent endometrial carcinoma”. J. Cancer. Res. Clin. Oncol., 2005, 131, 581.